[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"memory-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:memory-disorders":523},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,45,65,91,150,175,198,228,259,278,316,342,369,391,417,447,481,501],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100418184",false,"NCT04725409","Neural Correlates of Psychiatric Disorders","Neural Correlates of Neuropsychiatric Functions","Inclusion Criteria:\n\n* Undergoing SEEG monitoring at Vanderbilt University Medical Center\n* At least 18 years of age\n* English speaking\n\nExclusion Criteria:\n\n* Age \\\u003C18\n* Not able to complete questionnaires (e.g., unable to comprehend instructions or follow directions)","ALL","18 Years",{"count":18,"type":19},100,"ESTIMATED","OBSERVATIONAL","This ClincialTrials.gov record originally corresponded to the protocol approved under IRB # 202370. The study was expanded to include stimulation and recordings approved under new IRB #211037. The participant data originally acquired from IRB# 202370 will be included in this new record:\n\nThis study seeks to better understand the neural activity underlying neuro cognitive disorders. Resting state local field potential recordings will be collected from medically refractory epilepsy patients implanted with depth electrodes for seizure localization, and metrics of neural activity will be correlated with psychiatric symptoms as measured from questionnaires. Subjects will also participate in neuro cognitive tasks while neural recordings are performed, and\u002For receive neural stimulation through implanted depth electrodes. A better understanding of disordered neural activity underlying neuropsychiatric disorders may additionally contribute to novel methods for diagnosing, treating, and preventing these diseases.",[23,24],"Psychiatric Disorder","Memory Disorders",[26,27,28,29,30,31],"Depression","Stereo Electroencephalography (SEEG)","Anxiety","Obsessive compulsive disorder","Impulsivity","Memory","RECRUITING","2026-06-10",{"date":35,"type":36},"2026-06-12","ACTUAL",{"date":38,"type":36},"2021-03-31",{"date":40,"type":19},"2027-12",{"name":42,"class":43},"Vanderbilt University Medical Center","OTHER",1,{"id":46,"slug":4,"hasResults":10,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":44},"100643110","NCT07617506","Neural Basis of Human Working Memory","Inclusion Criteria:\n\n* Undergoing SEEG monitoring at Vanderbilt University Medical Center\n* Age \\>18\n* English speaking\n\nExclusion Criteria:\n\n* Age \\\u003C18\n* Not able to complete questionnaires (unable to comprehend instructions or follow directions)",{"count":18,"type":19},"This ClinicalTrials.gov entry corresponds to the Neural Basis of Human Working Memory protocol approved under Vanderbilt University Medical Center IRB #251231.\n\nThis study investigates the neural activity underlying human working memory, via local field potential changes (macro level) and\u002For single neuronal spiking changes (micro level) from depth electrodes placed for invasive seizure monitoring. Subjects will complete neurocognitive tasks while neural recordings are collected. Some patients will complete neurocognitive tasks while stimulation is applied via depth electrodes. Further understanding the neural activity changes underlying normal and impaired working memory may help to identify novel diagnostic methods and treatments for impaired working memory and may support the use of stimulation for treatment of memory disorders.",[24],[54,55,56,27],"Neural stimulation","Memory disorders","Working Memory","2026-06-09",{"date":59,"type":36},"2026-06-11",{"date":61,"type":36},"2025-06-04",{"date":63,"type":19},"2027-04",{"name":42,"class":43},{"id":66,"slug":4,"hasResults":10,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":10,"sex":15,"minAge":71,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":44},"100493750","NCT05709210","Pilot Study on the Feasibility of Using Smartphone Data as a Diagnostic Marker for Alzheimer's Disease","IMASMART","Inclusion Criteria:\n\n* Patient consulting in routine care in one of the CMRR\n* No sensory impairment that may compromise smartphone use\n\nExclusion Criteria:\n\n* Inability to perform MMSE or MMSE \\\u003C 20 ;\n* Other neurodegenerative condition (Parkinson's disease, Lewy body disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis)\n* Severe anxiety or depressive disorder HADS score ≥ 17\n* Terminal phase of a severe disease\n* Evidence of a lesion on MRI that may be involved in cognitive impairment","60 Years",{"count":73,"type":19},90,"INTERVENTIONAL",[76],"NA","This study will compare smartphone usage data between three groups of patients diagnosed with either a memory complaint, mild cognitive decline, or Alzheimer's disease.",[79,24],"Alzheimer Disease",[79,81,24],"Smartphone","2026-05-21",{"date":84,"type":36},"2026-05-26",{"date":86,"type":36},"2023-07-20",{"date":88,"type":19},"2026-10-20",{"name":90,"class":43},"Poitiers University Hospital",{"id":92,"slug":4,"hasResults":10,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":15,"minAge":16,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":74,"phases":101,"briefSummary":102,"conditions":103,"keywords":115,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100640275","NCT07580183","Spatial Scene Recognition Memory in Epilepsy Surgery","Investigations of Spatial Recognition Memory to Improve Cognitive Outcomes in Epilepsy Surgery","Inclusion Criteria:\n\n* Age 18 years or older\n* For Aims I and III: Diagnosis of focal epilepsy or temporal lobe lesion; patients undergoing evaluation for or having undergone epilepsy surgery\n* For Aim II: Healthy adult participants\n* Full-Scale IQ ≥ 70\n* English proficiency sufficient to understand and complete the task\n* For Aim I: Enrolled in or eligible for Emory University epilepsy surgery research registry\n* For Aim III: Undergoing clinically indicated stereoelectroencephalography (SEEG) at UC Davis Medical Center\n* Able to provide informed consent (or for Aim I retrospective component, prior consent in Emory registry)\n\nExclusion Criteria:\n\n* Full-Scale IQ \\\u003C 70\n* Inability to provide informed consent\n* For Aim III: Age \\> 55 years\n* For Aim II: History of neurological or psychiatric disorder (as applicable per study protocol)",true,"55 Years",{"count":100,"type":19},620,[76],"This study investigates the anatomical and physiological basis of spatial scene recognition memory in patients with temporal lobe epilepsy and temporal lobe lesions. Standard neuropsychological tests are insensitive to important memory deficits experienced by patients, particularly in spatial\u002Fscene memory, recollective experience, and familiarity processing. Using a validated virtual tour paradigm, the study examines how familiarity-based recognition and recall of spatial scenes relate to specific brain structures. In Aim I, a large cohort of patients with varied temporal lobe lesions at Emory University undergoes the virtual tour task with voxel-based lesion-symptom mapping to localize necessary brain regions. In Aim II, scalp event-related potentials and eye tracking in healthy participants at UC Davis characterize the temporal dynamics and lateralization of scene recognition. In Aim III, intracranial EEG recordings (including local field potentials and single-unit activity) in epilepsy surgery patients at UC Davis determine the precise network dynamics underlying spatial scene familiarity and recall. The long-term goal is to improve the prediction and prevention of cognitive morbidity from epilepsy surgery by providing a more complete model of spatial recognition memory circuits.",[104,105,106,24,107,108,109,110,111,112,113,114],"Focal Epilepsy","Temporal Lobe Epilepsy","Medically Refractory Epilepsy","Epilepsy Comorbidities","Epilepsy Intractable","Epilepsy Surgery","Epilepsy, Temporal Lobe","Memory Deficits","Memory Disorder, Spatial","Memory Dysfunction","Spatial Perception",[116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139],"spatial memory","recognition memory","familiarity","recollection","neural circuits of memory","phenomenology of memory","scene memory","virtual tour","epilepsy surgery","SEEG","stereo-electroencephalography","lesion-symptom mapping","network-symptom mapping","cognitive electrophysiology","event-related potentials","intracranial EEG","iEEG","parahippocampal gyrus","perirhinal cortex","hippocampus","tetrodes","deja vu","neuropsychology","consciousness","2026-05-06",{"date":142,"type":36},"2026-05-12",{"date":144,"type":36},"2024-07-01",{"date":146,"type":19},"2030-06-30",{"name":148,"class":43},"University of California, Davis",2,{"id":151,"slug":4,"hasResults":10,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":97,"sex":15,"minAge":157,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":74,"phases":160,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":44},"100490628","NCT05668598","Creation of an Ecological Tool Assessing Episodic Memory in Geriatrics","Creation of an Ecological Tool Assessing Episodic Memory in Geriatrics: an Adaptation of the Memory Test With Self-Initiated Items (MAI)","ECOTESTGER","Inclusion Criteria:\n\n* Male or female ≥ 70 ans\n* Person have good locomotion, move independently\n* Personne agree to participate\n\nGroupe 1 : 17≤MMSE≤24 (GRECO) Diagnosis of neurodegenerative diseases (major neurocognitive disorders: Alzheimer, mixed dementia, lobar frontotemporal degeneration, vascular dementia).\n\nGroupe 2 : MMSE ≥ à 25 (GRECO) Without neurodegenerative disease\n\nExclusion Criteria:\n\n* Person with legal protective measures\n* Person deprived of liberty\n* Mental retardation or MMSE≤ 16\n* Understanding verbal disorders\n* Visual major disturbances\n* Person with disease causing increased fatigue\n* Person with psychiatric pathology excepted anxiety disorder or depression with mild episodes.\n* Person not covered by French national health insurance","70 Years",{"count":159,"type":19},60,[76],"In this study the participants can be recruited via scheduled consultation and external institutions (associations, senior club..). Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease.\n\nStudy test is ecological MAI. This test are assigned in two groups (with or without neurocognitive disorders).",[24,163],"Neurocognitive Disorders",[165],"GERIATRICS","2026-05-05",{"date":168,"type":36},"2026-05-08",{"date":170,"type":36},"2023-03-08",{"date":172,"type":19},"2028-03-09",{"name":174,"class":43},"Centre Hospitalier de Lens",{"id":176,"slug":4,"hasResults":10,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":10,"sex":15,"minAge":181,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":184,"conditions":185,"keywords":186,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":44},"100559488","NCT06564779","Development, Standardisation and Standardisation Project for a New Memory Assessment","NEM","Inclusion Criteria:\n\n* Age ≥ 50 years\n* Ability to understand judged sufficient by the assessor;\n* Amnesic MCI profile (Petersen, 2003) during the 1st medical consultation prior to the assessment being prescribed.\n\nExclusion Criteria:\n\n* Severe auditory and\u002For visual sensory impairment not compatible with neuropsychological assessment;\n* Judged fit to take the test by the assessor;\n* Patient under guardianship, curatorship or family guardianship;\n* Opposition to data processing.","50 Years",{"count":183,"type":19},150,"Episodic memory (EM) is a neuropsychological marker of Alzheimer's disease (AD) (Thomas-Anterion, 2006). Current tests for its assessment do not take into account the identity and emotional aspects of memory (Van der Linden et al., 2018). However, there are models that integrate links with identity, self-awareness and experience. Pause et al. (2013) propose criteria to create ecological tools, including consideration of the emotional valence of memories and the spatio-temporal context of acquisition. In line with these criteria, we have developed a new tool: the NEM (New evaluation of Episodic Memory). Preliminary studies show different response profiles on the NEM among patients (Launay et al., 2023). We now want to evaluate the relevance of this tool in the differential diagnosis of AD.",[24],[187,188],"Alzheimer","Episodic memory","2026-04-29",{"date":191,"type":36},"2026-04-30",{"date":193,"type":36},"2024-11-22",{"date":195,"type":19},"2028-11",{"name":197,"class":43},"University Hospital, Tours",{"id":199,"slug":4,"hasResults":10,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":97,"sex":15,"minAge":71,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":207,"conditions":208,"keywords":214,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":227},"100560992","NCT06584357","Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia","Bio-Hermes-002","Inclusion Criteria:\n\nPre-screening Inclusion Criteria\n\nParticipants must meet ALL of the following criteria to progress to Visit 1 (Screening):\n\n1. Participant is between 60 to 90 years of age (inclusive) at the time of consent; and\n2. Participant has a study partner who has sufficient and frequent contact with the participant (defined as at least 8 hours of contact a week) and is able to provide accurate information regarding the participant's cognitive and functional abilities.\n\nCore Study Inclusion Criteria\n\nParticipants must meet ALL of the following criteria, in addition to the Pre-screening Inclusion Criteria, for entry into the study:\n\n1. Participants must provide written consent in the IRB-approved or Ethics Committee (EC) approved informed consent form or have a legally authorized representative (LAR) provide written consent on the participant's behalf in accordance with local and national guidance and regulation;\n2. Participants must be willing to undergo an MRI brain scan within 90 days and an amyloid and tau PET scan within 120 days of signing informed consent;\n3. Participants must be willing to comply with all study procedures as outlined in the informed consent, including blood sampling, genetic testing, and storage of biospecimens for future research;\n4. Fluency in the language of the tests used at the study site;\n5. Participants must be willing to be contacted for possible participation in clinical research trials once their participation in this study ends; and\n6. Participants must have a Mini-Mental State Exam (MMSE) score of 16 to 30 inclusive at screening.\n\nExclusion Criteria:\n\nPre-screening Exclusion Criteria\n\nParticipants who meet ANY of the following criteria will not be eligible to progress to Visit 1 (Screening):\n\n1. Participant is unable to undergo amyloid and tau PET scans due to self-reported pregnancy, sensitivity to ligands being used, poor venous access, contraindication to PET, or planned or recent exposure to ionizing radiation that in combination with the planned administration of amyloid radioligand would result in a cumulative exposure that exceeds recommended local guidelines;\n2. Participants who have reported or have a known negative amyloid PET scan in the past 6 months;\n3. Participants with any known contraindication to brain MRI scan;\n4. Participants with history of stroke or seizures within 1 year of the Pre-Screening Visit;\n5. Participants with history of cancer within the past 5 years with the exception of non-melanoma skin cancer or prostate cancer in situ;\n6. Participants with known or suspected alcohol or drug abuse or dependence within 1 year of the Pre- Screening Visit;\n7. Participants who report any current unstable psychiatric symptoms that could interfere with study procedures or impact study data (e.g., uncontrolled depression);\n8. Participants who have received any potential disease modifying AD treatment within 6 months prior to the Pre-screening Visit; and\n9. Participants with known history or self-report to be Human Immunodeficiency Virus (HIV) Positive unless controlled by antiviral medication.\n\nCore Study Exclusion Criteria\n\nParticipants who meet ANY of the following criteria, in addition to the Pre-screening Exclusion Criteria, will not be eligible to enroll into the study:\n\n1. Participants who, in the opinion of the Site Principal Investigator, have serious or unstable medical conditions that would prohibit their completion of all study procedures and data collection;\n2. Participants who have serious or unstable medical conditions that would likely preclude their participation in an interventional research trial;\n3. Participants with self-reported, untreated conditions such as vitamin B12 or folate deficiency or bladder infections that in the opinion of the Site Principal Investigator could contribute to cognitive impairment;\n4. Participants who have completed cognitive testing within 1 month of Visit 1 (Screening) where the Site Principal Investigator believes the participant's exposure may cause practice effect;\n5. Participants who have any neurological disorder affecting the central nervous system, other than AD, that may be contributing to cognitive impairment (e.g., Parkinson's disease, other dementias, multiple concussions or seizures) as deemed significant by the Site Principal Investigator;\n6. Participants with a Geriatric Depression Scale (GDS) score greater than or equal to 8 at Visit 1 (Screening) and is deemed to be clinically significantly depressed by the Site Principal Investigator;\n7. Participants with a Rey Auditory Verbal Learning Test (RAVLT) t-score of ≥ 1.2 standard deviation above the mean. For non-African Americans, calculate age-sex-education adjusted t-scores. For African American participants, use the MOANS to calculate the age-education adjusted t-scores;\n8. Participants weighing less than 110 pounds;\n9. Participants who are direct employees or family members of direct employees of the participating investigators' sites;\n10. Participants who are direct employees of the Sponsor;\n11. Participants who, in the opinion of the investigator, are unable to complete cognitive testing due to inadequate visual or auditory acuity; and\n12. For participants completing the RetiSpec retinal scan: Those with a known history of contraindication or allergy to Tropicamide 1% (pupil dilation drop).\n\nLongitudinal Sub-Study Eligibility\n\nInclusion Criteria:\n\nParticipants must meet ALL of the following criteria for entry into the sub-study:\n\n1. Participants who completed the Bio-Hermes-002 Core Study;\n2. Are willing to complete phone call visits with site staff every three months and return to the clinic for an annual evaluation; and\n3. Are willing to complete annual PET scans for both amyloid and tau scans.\n\nExclusion Criteria:\n\nParticipants who meet ANY of the following criteria will not be eligible for entry into the sub-study:\n\n1. Those who are enrolled or intend to enroll into a clinical trial for Alzheimer's disease with a potential disease-modifying intervention;\n2. Participants who have serious or unstable medical conditions that would likely preclude their participation in an interventional research trial;\n3. Those who intend to use medications outside clinical research studies approved by regulatory authorities to modify Alzheimer's disease pathology.","90 Years",{"count":206,"type":19},1200,"Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.",[209,210,211,212,24,213],"Mild Cognitive Impairment","Alzheimer's Disease","Alzheimer's Disease, Early Onset","Memory Loss","Memory Impairment",[210,211,209,215,216,212,24,213],"Older Volunteers","Healthy Volunteers","2026-04-13",{"date":219,"type":36},"2026-04-15",{"date":221,"type":36},"2024-09-26",{"date":223,"type":19},"2028-07",{"name":225,"class":226},"GAP Innovations, PBC","INDUSTRY",26,{"id":229,"slug":4,"hasResults":10,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":10,"sex":15,"minAge":98,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":74,"phases":238,"briefSummary":239,"conditions":240,"keywords":244,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":149},"100581676","NCT06853405","Nutrition-based Interventions to Prevent Cognitive Decline","NUTRIMIND: Nutrition-based Interventions to Prevent Cognitive Decline","NUTRIMIND","Inclusion Criteria:\n\n* Aged from 55 to 85 years old;\n* At least 4 years in the regular school system;\n* Higher individual risk for dementia defined as a score ≥6 points on the Cardiovascular Risk Factors, Aging and Dementia Dementia Risk Score (CAIDE).\n\nExclusion Criteria:\n\n* Montreal Cognitive Assessment (MoCA) score lower than the validated cutoff points defined as 2 standard deviations below the normative reference value for the corresponding age and education in the Portuguese population;\n* Having a medical condition limiting the participation in the intervention (e.g., blindness, amputation…);\n* Lack of autonomy in daily activities;\n* Diagnosis of dementia or major incapacity.","85 Years",{"count":237,"type":19},120,[76],"This study intends to evaluate the feasibility and the effectiveness of an innovative and integrated nutrition-based intervention addressing key modifiable risk factors for dementia while meeting participants' preferences for nutrition-related sessions. The intervention will include lifestyle group sessions regarding nutrition education and physical activity, individualized cognitive training at home, as well as clinical nutrition consultations.",[241,242,24,243,163],"Cognitive Dysfunction","Cognition Disorder","Cognitive Impairment",[245,246,241,247,248,249],"Healthy Aging","Dementia","Diet, Food and Nutrition","Diet, Mediterranean","Randomized Controlled Trial","2025-11-27",{"date":252,"type":36},"2025-12-05",{"date":254,"type":36},"2025-01-27",{"date":256,"type":19},"2026-08",{"name":258,"class":43},"Instituto de Saude Publica da Universidade do Porto",{"id":260,"slug":4,"hasResults":10,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":10,"sex":15,"minAge":98,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":269,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":276,"locationsCount":44},"100612488","NCT07254234","A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's Disease","Exploratory Study to Assess Utility of RetiSpec Artificial Intelligence Powered Retinal Imaging Solution in Detecting Amyloid Pathology in United Arab Emirates Nationals With Mild Impairment of Cognition","Inclusion Criteria:\n\n* Participants who are overtly healthy as determined by medical evaluation, including medical history and physical examination.\n* Have mild memory complaints or a diagnosis of mild cognitive impairment.\n* Have undergone genotyping for apolipoprotein E (APOE) and are willing to make results available to the investigator.\n* Montreal Cognitive Assessment (MoCA) score of greater than or equal to 22 and less than or equal to 28.\n\nExclusion Criteria:\n\n* Have any medical condition that, in the opinion of the investigator, would be a contraindication to participation in the study.\n* Have an existing diagnosis of AD or other dementia.\n* Have contradictions to or an allergy to the ophthalmic dilating agents.\n* Have known diagnosis of severe glaucoma or severe cataracts; have a significant refractive error (more than 12 diopters \\[D\\] of spherical equivalent refraction); or have any ocular media opacity that prevents imaging of the retina (that is, severe cataract). Note: mild to moderate cataracts or vision correction with glasses or contact lenses are not exclusion criteria.\n* Current or previous treatment with anti-amyloid medications.\n* Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.",{"count":266,"type":19},200,"The purpose of this study is to test the use of a screening tool to detect changes in the eye that are associated with Alzheimer's disease in adult participants with memory issues. For each participant, the study will last up to one month and requires one visit to the research site.",[241,24],"NOT_YET_RECRUITING","2025-11-20",{"date":272,"type":36},"2025-11-28",{"date":274,"type":19},"2025-12",{"date":256,"type":19},{"name":277,"class":226},"Eli Lilly and Company",{"id":279,"slug":4,"hasResults":10,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":74,"phases":286,"briefSummary":287,"conditions":288,"keywords":297,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":44},"100587627","NCT06930846","HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)","HOBSCOTCH-CA","CA Participants will be referred to the study by their providers (Oncologist) who will be made aware of the study and inclusion\u002Fexclusion criteria. Inclusion Criteria 2. - 5. and Exclusion Criteria 1. - 3. will be confirmed by referring providers. Participants who learn about the study here and elsewhere will be instructed on how to confirm their eligibility with their provider.\n\nInclusion Criteria for CA Participant:\n\n1. 18 + years\n2. Service members, Veterans and civilians with a diagnosis of brain cancer (excluding glioblastoma)\n3. Diagnosis of primary brain tumor with expected survival of 2 years or greater (e.g., low-grade glioma, oligodendroglioma, IDH mutant astrocytoma, meningioma) defined as the presence of a primary lesion on neuroimaging (CT or MRI), confirmed by histopathological examination (Note: some patients being treated for meningioma may be treated with radiotherapy without need for initial histopathologic confirmation)\n4. Patients undergoing surgical and\u002For radiation therapy will have completed their treatment at least 3 months prior to being enrolled in trial (Note: patients receiving chemotherapy or other systemic therapy will be included)\n5. Stable on all CNS acting medications for one month prior to enrollment\n6. Subjective cognitive complaints\n7. Literate and proficient in English\n8. Internet access for the pre-session and Session 1 of the HOBSCOTCH-CA program; telephone access for sessions 2-8\n\nExclusion Criteria for CA Participant:\n\n1. Presence of a neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease)\n2. Acute psychiatric disorder or substance abuse\n3. Patients with glioblastoma (GBM)\n\nInclusion Criteria for CA Participant Caregiver:\n\n1. Age 18 +\n2. Caregiver to a patient with a confirmed diagnosis of brain cancer\u002Ftumor survivor\n3. CA Subject has given permission for their caregiver to participate\n4. Literate and proficient in English\n5. Internet access (for Pre-HOBSCOTCH and Session 1)\n6. Telephone access (for Session 8)\n\nExclusion Criteria for CA Participant Caregiver:\n\n1. Significant visual impairment precluding reading or writing\n2. No reliable telephone or internet access",{"count":285,"type":19},125,[76],"The purpose of this study is to assess the ability of the home-based intervention, HOBSCOTCH-CA, to improve the quality of life and cognitive function in Service Members, Veterans and civilians who are survivors of brain cancer or a brain tumor (CA participants). This study will also assess the ability of the HOBSCOTCH-CA program to improve quality of life in caregivers of patients with brain cancer\u002Ftumor and to reduce caregiver burden. Enrolling with a Caregiver is optional for CA participants.\n\nInvestigators will compare two groups of CA participants and their Caregiver (enrolling with a Caregiver is optional): one who receives HOBSCOCTCH-CA immediately (Group 1) and another group that will receive HOBSCOTCH-CA (Group 2) after a 3-month waiting period. Participants will be in the study for about 6 months total.\n\nHOBSCOTCH-CA involves 45 to 60 minute one on one virtual sessions with a certified Cognitive Coach including a \"pre\" program session and 8 weekly sessions thereafter. Participants will learn about problem solving therapy and mindfulness or relaxation training. CA participants are asked to do short homework assignments and keep a brief daily diary on a smart phone app. All participants complete study questionnaires or surveys at enrollment, 3 months later and at 6 months (at the end of the study).",[289,290,291,292,293,294,295,296,241,213,24,113],"Brain Cancer","Brain Tumor","Brain Neoplasms","Primary Brain Tumor","Low-grade Glioma","Oligodendroglioma","Meningioma","Low Grade Astrocytoma",[298,299,300,301,302,55,303,304,305,306],"Brain cancer survivor","Brain tumor survivor","Cognition","Self-management","Cognitive training","Cognitive remediation","Caregiver","Caregiver burden","Mindfulness","2025-11-18",{"date":309,"type":36},"2025-11-21",{"date":311,"type":36},"2025-11-03",{"date":313,"type":19},"2028-12",{"name":315,"class":43},"Dartmouth-Hitchcock Medical Center",{"id":317,"slug":4,"hasResults":10,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":10,"sex":15,"minAge":322,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":74,"phases":325,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":341,"locationsCount":44},"100589246","NCT06951919","HOBSCOTCH-MS-Efficacy Trial","HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH) - Multiple Sclerosis (MS) - Efficacy Trial","Inclusion Criteria:\n\n* Inclusion Criteria - MS Participant\n\n  * Age 20 - 75 years\n  * Diagnosis of relapsing or progressive MS\n  * Education of at least Grade 12 or GED\n  * Fluent in English\n  * Subjective cognitive and memory challenges\n  * Internet access\n  * Telephone access\n\nInclusion Criteria - Caregiver Participant\n\n* 20 years +\n* Fluent in English\n* Caregiver to a MS Participant\n* Participant MS has given permission to Caregiver to enroll with them\n* Internet access\n* Telephone access\n\nExclusion Criteria:\n\n* Exclusion Criteria MS Participant\n\n  * Current diagnosed psychiatric disorders (e.g., schizophrenia, bipolar disorder or substance use disorder).\n  * Other neurological disorder such as epilepsy, brain tumor, severe brain injury or mild to moderate brain injury with a history of 30 or more minutes' loss of consciousness, or other disorder that would confound the focus on MS\n  * Diagnosed developmental attention, learning, or intellectual disorder; sensory, motor, or physical disability that would prevent engagement with the intervention or render the person unable complete study outcome measures\n  * Exacerbation of MS symptoms (relapse) or ongoing steroid treatment within three months of study enrollment\n  * Significant visual impairment precluding reading or writing\n  * Lack of access to the technical resources (e.g., internet access, telephone) required for participation\n\nExclusion Criteria - Caregiver Participant\n\n* Significant visual impairment precluding reading or writing\n* No reliable telephone or internet access","20 Years","75 Years",{"count":285,"type":19},[76],"The purpose of this study is to assess the ability of the home-based intervention, HOBSCOTCH-MS to improve the quality of life and cognitive function in Service Members, Veterans and civilians who have multiple sclerosis with cognitive and memory problems (MS participants). This study will also assess the ability of the HOBSCOTCH-MS program to improve quality of life in caregivers of patients with multiple sclerosis and to reduce caregiver burden. Enrolling with a Caregiver is optional for MS participants.\n\nInvestigators will compare two groups of MS participants and their Caregiver (enrolling with a Caregiver is optional): one who receives HOBSCOTCH-MS immediately (Group 1) and another group that will receive HOBSCOTCH-MS (Group 2) after a 3-month waiting period. Participants will be in the study for about 6 months total.\n\nHOBSCOTCH-MS involves 45 to 60 minute one on one virtual sessions with a certified Cognitive Coach including a \"pre\" program session and 8 weekly sessions thereafter. Participants will learn about problem solving therapy and mindfulness or relaxation training. MS participants are asked to do short homework assignments and both MS and Caregiver participants are asked to keep a brief daily diary on a smart phone app. All participants complete study questionnaires or surveys at enrollment, 3 months later and at 6 months (at the end of the study).\n\nAfter completing the intervention, MS Participants and their Caregivers may also participate in an optional one-time Key Informant Interview for qualitative analysis in an effort to further adapt and improve the HOBSCOTCH-MS in the future.",[328,241,24,213,113],"Multiple Sclerosis",[300,330,331,332,24,333,334,306],"Self-Management","Cognitive Remediation","Cognitive Training","Caregivers","Caregiver Burden","2025-10-27",{"date":337,"type":36},"2025-10-29",{"date":339,"type":36},"2025-09-09",{"date":313,"type":19},{"name":315,"class":43},{"id":343,"slug":4,"hasResults":10,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":97,"sex":15,"minAge":16,"maxAge":98,"enrollmentInfo":348,"targetDuration":4,"studyType":74,"phases":349,"briefSummary":351,"conditions":352,"keywords":356,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":44},"100484896","NCT05594017","Pharmacological Modulation of Brain Oscillations in Memory Processing","Behavioral and Pharmacological Manipulation of Time Cell Activity in the Human Mesial Temporal Lobe","Patient inclusion criteria:\n\n1. Age 18 - 55 years, all races\u002Fethnicities, and both genders are eligible.\n2. Candidates for pre-operative evaluation using stereo intracranial electrodes and admission to the Epilepsy Monitoring Unit (EMU) as determined independently by the patient's treating physician as part of the patient's routine medical care.\n3. Able to read, understand, and provide written, dated informed consent prior to screening.\n4. In good general health, aside from a history of epilepsy, as ascertained by medical history, physical examination (PE), clinical laboratory evaluations, and ECG.\n5. Body mass index between 18-35 kg\u002Fm2.\n\nPatient exclusion criteria:\n\n1. Has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results according to the study physician.\n2. Female that is pregnant, breastfeeding, or has a positive pregnancy test at screening or baseline. Note that pregnant patients are excluded from undergoing iEEG generally and all patients undergo a positive screening urine test for drugs of abuse at screening: cannabinoids, cocaine, amphetamines, barbiturates, opiates not otherwise explained by their prescribed medications.\n3. History of renal insufficiency.\n4. Unstable cardiac syndrome or active cardiac symptoms.\n5. Patients with liver failure.\n6. Patients with BPH.\n7. Patients with autoimmune neuropathy.\n8. Patients with uncontrolled hyperthyroidism.\n9. Patients with a history of dementia.\n10. Patient with a history of delirium after using transdermal scopolamine.\n11. History of narrow-angle glaucoma.\n12. History of pyloric obstruction or paralytic ileus.\n13. History of myasthenia gravis, obstructive uropathy, porphyria, or myasthenia gravis.",{"count":159,"type":19},[350],"EARLY_PHASE1","The goal of this study is to learn about the effects of scopolamine (an anticholinergic drug) on areas of the brain involved in memory, and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed.\n\nThe main questions it aims to answer are 1) whether scopolamine changes memory activity solely at encoding (the time when the person perceives and determines to remember an item or event) as has previously been found, or if it also can selectively impact retrieval (when the item or event which has been processed is recalled or remembered), and 2) what the nature of the brain activity changes is.\n\nParticipants will complete two treatment arms. One of these will be with the drug, and the other will be with a saline solution, so that the participants are unaware which session the actual drug has been received. Patients will complete a verbal and\u002For spatial task each of the two days. An anesthesiologist will administer either the drug or the saline at a critical point which addresses both of the research questions.\n\nResearchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and at what time point during memory formation.",[353,354,355,24,212],"Epilepsy","Seizures","Cognitive Impairment, Mild",[357,358,359],"oscillatory changes","cholinergic antagonist","muscarinic antagonist","2025-09-29",{"date":362,"type":36},"2025-10-03",{"date":364,"type":36},"2019-08-01",{"date":366,"type":19},"2027-05-31",{"name":368,"class":43},"University of Texas Southwestern Medical Center",{"id":370,"slug":4,"hasResults":10,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":323,"enrollmentInfo":375,"targetDuration":4,"studyType":74,"phases":376,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":44},"100444286","NCT05065450","Amygdala Memory Enhancement","Mechanisms of Amygdala-Mediated Memory Enhancement in Humans","Inclusion Criteria:\n\n* Must be able to understand and speak English.\n* Able to provide informed consent.\n* Diagnosed with epilepsy.\n* Scheduled to undergo long-term intra-cranial video monitoring for seizure onset localization.\n* Must be implanted with intracranial depth electrodes to the left or right amygdala, hippocampus, and parahippocampal\u002Fperirhinal cortices.\n\nExclusion Criteria:\n\n* Unable to understand and speak English.\n* Unable to provide informed consent.\n* Not diagnosed with epilepsy.",{"count":73,"type":19},[76],"The objective is to understand how amygdala activation affects other medial temporal lobe structures to prioritize long-term memories. The project is relevant to disorders of memory and to disorders involving affect and memory, including traumatic brain injury and post-traumatic stress disorder.",[379,353,24,380,243,381],"Brain Diseases","Traumatic Brain Injury","Post Traumatic Stress Disorder","2025-07-14",{"date":384,"type":36},"2025-07-17",{"date":386,"type":36},"2021-11-01",{"date":388,"type":19},"2027-11-01",{"name":390,"class":43},"Washington University School of Medicine",{"id":392,"slug":4,"hasResults":10,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":97,"sex":15,"minAge":16,"maxAge":396,"enrollmentInfo":397,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":399,"conditions":400,"keywords":404,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":44},"100548920","NCT06427265","Machine Learning-based Longitudinal Study of Post-ICU Syndrome Development Trajectory in Critically Ill Patients and Construction of Clinical Early Warning Models: a Research Protocol for Longitudinal Study","Inclusion Criteria patients :\n\n* Length of stay in ICU ≥24h;\n* Age ≥18 years old;\n* Conscious when leaving ICU, communicating with investigators without barriers;\n* Informed consent. Family members：\n* One family member ≥18 years of age was selected for each patient;\n* Assume the main role of caring for patients and medical decision-making;\n* No history of mental illness or other serious organic diseases;\n* Informed consent and voluntary participation in this study.\n\nExclusion Criteria patients :\n\n* Have been in ICU for more than 24h within 3 months before this admission;\n* Transferred to another ICU;\n* Cognitive impairment existed before ICU admission (BDRS \\> 4 points);\n* Severe hearing impairment, dysarthria, etc., which cannot be followed up;\n* Unable to complete the questionnaire survey due to serious illness.\n\nFamily members:\n\n* Family members refuse to participate in the study due to their own reasons;\n* Severe hearing and language impairment, unable to cooperate with researchers.","100 Years",{"count":398,"type":19},840,"This project intends to track and evaluate whether post-ICU syndrome will occur 7 days, 1 month, 3 months and 6 months after ICU patients are transferred out of the ICU through a longitudinal study, apply the latent category growth model to identify different trajectory patterns of post-ICU syndrome in critically ill patients, and use modern machine learning models to build an early warning model of the trajectory patterns of post-ICU syndrome.",[401,402,243,403,24],"Intensive Care Unit Syndrome","Prediction","Sleep Disorder",[405,406,407],"Post-icu syndrome","Prediction model","Development Trajectory","2025-05-26",{"date":410,"type":36},"2025-05-31",{"date":412,"type":36},"2023-12-01",{"date":414,"type":19},"2026-06-01",{"name":416,"class":43},"The Affiliated Hospital Of Guizhou Medical University",{"id":418,"slug":4,"hasResults":10,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":10,"sex":15,"minAge":157,"maxAge":423,"enrollmentInfo":424,"targetDuration":4,"studyType":74,"phases":426,"briefSummary":427,"conditions":428,"keywords":430,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":44},"100501241","NCT05806697","Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study","INSIGHT-2","Inclusion Criteria:\n\n* Subjects that previously participated in the INSIGHT cohort\n* Aged 70 to 95 years old\n* Having signed an informed consent\n* Willing to and able undergo a baseline PET amyloid imaging\n* Affiliating to the French health-care system\n* Having an identified informant who has sufficient contact with the participant and has to be able to provide accurate information, at least by phone, about the participants' cognitive and functional abilities.\n\nExclusion Criteria:\n\n* Clinical Dementia Rating ≥1 at screening\u002Fbaseline visit only\n* Fulfilling research diagnostic criteria for any type of dementia-related disorder at screening visit (clinical AD, Dementia with Lewy Bodies \\[DLB\\], fronto-temporal dementia \\[FTD\\], vascular dementia, chronic traumatic encephalopathy \\[CTE\\], Limbic-predominant Age-related TDP-43 Encephalopathy \\[LATE\\], Primary age-related tauopathy \\[PART)\n* Presence of any medical condition associated with a long-term risk of cognitive impairment or dementia including Parkinson's disease, brain tumor, subdural hematoma, vascular malformations, territorial stroke (excluding smaller watershed strokes), chronic hydrocephalus, traumatic brain injury with neurological sequelae, active alcohol\u002Fdrug abuse, major depressive disorder, schizophrenia and bipolar disorder\n* Current serious or unstable illnesses (including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic or hematologic disease) that might make the subject's participation in an investigational trial unsafe\n* Any contraindications for MRI\u002F PET scan procedure (claustrophobia, ferromagnetic object in the body), to FDG or to 18F-Florbetapir (Amyvid®).\n* Hypersensitivity to the active substance or to any of the excipients of 18F-Florbetapir (Amyvid®).\n* Participation in any clinical trial of an investigational product in the last 30 days before the screening (during all study duration co-inclusion in other clinical trial of an investigational product or observational research \\[biomarker cohort e.g.\\] will be possible but the information would need to be recorded).\n* Unable to comply with protocol requirements in the opinion of the investigator\n* Being under guardianship (safeguard of justice, curatorship or guardianship)\n* Residence in skilled nursing facility, including nursing homes (EHPAD).","95 Years",{"count":425,"type":19},240,[76],"A regional, single-center, prospective, observational academic cohort will follow subjects who previously participated in the INSIGHT study and who agree an extension of their follow-up in the INSIGHT-2 research for additional 5-6 years. An annual multimodal evaluation (cognitive, oculomotor, biological and neuroimaging) will be proposed in order to describe the natural history of preclinical Alzheimer's disease (AD). The primary endpoint is the conversion to the symptomatic stage in subjects at risk, identified by positive amyloid staining (A+) on florbetapir positron emission tomography (PET) imaging. The size of the cohort is estimated to around 240 participants (61 A+ subjects) among the 318 participants included in the main cohort (88 A+ subjects). The follow-up in the INSIGHT-2 cohort will be lightened compared to that of the main cohort with an annual frequency of visits rather than a six-monthly one.",[79,429,24],"Memory Complaint",[431,432,433,434,435,436],"risks factors","brain amyloid load","neurosciences","neurology","memory complaint","memory disorders","2025-01-21",{"date":439,"type":36},"2025-01-23",{"date":441,"type":36},"2023-04-14",{"date":443,"type":19},"2030-10-09",{"name":445,"class":446},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":448,"slug":4,"hasResults":10,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":97,"sex":15,"minAge":181,"maxAge":235,"enrollmentInfo":453,"targetDuration":4,"studyType":74,"phases":454,"briefSummary":455,"conditions":456,"keywords":463,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":44},"100525638","NCT06124339","Brain Health Virtual Reality Study","Interventions to Promote Brain Health Virtual Reality Study","Inclusion Criteria:\n\n1. 50-85 years of age\n2. Fluent in English\n3. Can safely ride a stationary bike\n\nExclusion Criteria:\n\n1. Dementia\n2. History of a neurological disorder\n3. Severe sensory deficits\n4. Inability to perform intervention (e.g., inability to cycle safely)\n5. Contraindications to MRI scan (e.g., pacemaker)\n6. Fear of needles\u002F blood\n7. Prior history of fainting due to sight of needles of blood",{"count":183,"type":19},[76],"The Interventions for Brain Health Virtual Reality Study is a NIH-funded clinical research trial at the University of California San Diego (UCSD) Health under the supervision of the study principal investigator Dr. Judy Pa. The overarching goal of this trial is to use a novel virtual reality (VR) based intervention that simultaneously engages physical and cognitive activity aimed at improving brain health and cognition in older adults. The investigators will compare 3 types of interventions: physical activity, VR cognitive activity, and combined VR physical and cognitive activity over 16 weeks to evaluate physical and brain health changes.",[457,458,212,213,459,112,24,209,460,461,462],"Aging","Aging Problems","Memory Disorders in Old Age","Cognitive Decline","Cognitive Change","Cognition Disorders in Old Age",[464,465,466,467,468,469,470,471],"Virtual Reality","technology","intervention","exercise","cycling","memory","brain health","aging","2024-07-08",{"date":474,"type":36},"2024-07-10",{"date":476,"type":36},"2023-08-08",{"date":478,"type":19},"2029-02-01",{"name":480,"class":43},"University of California, San Diego",{"id":482,"slug":4,"hasResults":10,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":97,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":74,"phases":490,"briefSummary":491,"conditions":492,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":499,"locationsCount":44},"100510646","NCT05929144","Optimization of MRI Sequences Used in the Study of Neurodegenerative Diseases","Optimization of MRI Sequences Used in the Study of Neurodegenerative Diseases at Inserm U1237 NeuroPresage Team, Cyceron Center in Caen","IRMtests","Inclusion Criteria:\n\n* Healthy volunteers of legal age\n* Affiliation with a social security scheme or beneficiary of such a scheme\n* Signing of the protocol informed consent\n* For women of childbearing age or capacity, a urine pregnancy test before inclusion\n\nExclusion Criteria:\n\n* Protected persons in accordance with articles L. 1121-5 to L.1121-8 of the Public Health Code: protected adults, pregnant and nursing women\n* Presence of contraindications to MRI examination without contrast agents injection\n* Presence of a chronic neurological or psychiatric condition (including substance use disorder)\n* History of brain disease (vascular, degenerative, malformative, tumour, or head trauma with loss of consciousness for more than one hour)\n* Current or recent use of medications that may interfere with imaging (psychotropic drugs, antihistamines with anticholinergic action, antiparkinsonian drugs, benzodiazepines including muscle relaxants, long-term steroidal anti-inflammatory drugs, antiepileptic drugs, central painkillers)",{"count":489,"type":19},40,[76],"The Inserm NeuroPresage team has been using MRI for more than 20 years in the study of normal ageing and memory pathologies to further the understanding and the characterization of early diagnosis and the cerebral substrates of cognitive deficits in patients, particularly in the context of neurodegenerative diseases.\n\nTwo years ago, a new 3T MRI camera was installed at the Cyceron centre. It is more efficient and should make it possible to obtain better quality images and\u002For to reduce the time required to acquire these images.\n\nIn this context, it seems important to test the different sequences that we classically use in our studies, or that we plan to implement in our next studies (learning and text retrieval fMRI task), in order to optimize them, with a view to integrating them in our future studies.",[24],"2023-06-26",{"date":495,"type":36},"2023-07-03",{"date":497,"type":36},"2023-05-05",{"date":223,"type":19},{"name":500,"class":43},"University Hospital, Caen",{"id":502,"slug":4,"hasResults":10,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":74,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":522},"100354387","NCT03894254","Predictive Factors of Autonomy Loss in Real-life Cohort","Predictive Factors Associated With Impairment in Functional Autonomy in a Regional Real-life Cohort of Patients With Alzheimer's Disease or Related Disorders (ADRD)","MEM-AURA","Inclusion Criteria:\n\n* Patients aged 18 years and older, undergoing a medical visit in a memory center or neuro-cognition service\n* Patients living at home or in housing\n* Patients with memory impairment, at all stage of the disease\n\nExclusion Criteria:\n\n* Patients in institution\n* Patients under legal protection\n* Patients with a hearing or visual impairment, which prevents carrying out examinations",{"count":509,"type":19},5400,[76],"The Alzheimer's disease or related disorders (ADRD) are among the most disabling diseases because of their main features such as cognitive impairment, loss of functional autonomy and behavioural disorders. In absence of current curative treatment, the identification of the predictive risk factors of progression of the disease, evaluated through its main symptoms, represents a major stake of public health. The Investigators aim at developing a regional database, which includes the patient medical records on a prospective basis, in collaboration with the medical and administrative staff and with the University hospital computer science departments.\n\nThe main objective is to study the predictive factors associated with change in functional autonomy level, measured every 6 to 12 months in centres across Region Auvergne Rhone-Alpes in France.\n\nThe real-life study population will consist in about 5400 patients with ADRD. The inclusion period will be of 3 years, the length of follow-up of each patient will be of 10 years max for a total study length of 13 years.",[24],"2022-04-25",{"date":515,"type":36},"2022-05-02",{"date":517,"type":36},"2020-09-09",{"date":519,"type":19},"2032-03-01",{"name":521,"class":43},"Hospices Civils de Lyon",5,""]